This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2021 Oct;9(10):e001701corr1.

doi: 10.1136/jitc-2020-001701corr1.

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

No authors listed

PMID: 34645676
PMCID: PMC8515457
DOI: 10.1136/jitc-2020-001701corr1

Published Erratum

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

No authors listed. J Immunother Cancer. 2021 Oct.

. 2021 Oct;9(10):e001701corr1.

doi: 10.1136/jitc-2020-001701corr1.

PMID: 34645676
PMCID: PMC8515457
DOI: 10.1136/jitc-2020-001701corr1

No abstract available

PubMed Disclaimer

Erratum for

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Ressler JM, Karasek M, Koch L, Silmbrod R, Mangana J, Latifyan S, Aedo-Lopez V, Kehrer H, Weihsengruber F, Koelblinger P, Posch C, Kofler J, Michielin O, Richtig E, Hafner C, Hoeller C. Ressler JM, et al. J Immunother Cancer. 2021 Feb;9(2):e001701. doi: 10.1136/jitc-2020-001701. J Immunother Cancer. 2021. PMID: 33608376 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources